ライフサイエンスコーパス: follicular lymphoma

1 resent in approximately 20% of patients with follicular lymphoma.

2 clinical trials in rheumatoid arthritis and follicular lymphoma.

3 rash (four [50%] of eight) for patients with follicular lymphoma.

4 patients with newly diagnosed advanced-stage follicular lymphoma.

5 ypes, in particular mantle cell lymphoma and follicular lymphoma.

6 a platform for response-adapted treatment of follicular lymphoma.

7 subtype, and 1 family displayed early-onset follicular lymphoma.

8 tuximab in patients with relapsed/refractory follicular lymphoma.

9 class, oral EZH2 inhibitor, in patients with follicular lymphoma.

10 ostat is a novel treatment for patients with follicular lymphoma.

11 lerated and active in patients with relapsed follicular lymphoma.

12 ation of rituximab as maintenance therapy in follicular lymphoma.

13 + R (BR) alone in relapsed/refractory (R/R) follicular lymphoma.

14 er-derived diffuse large B-cell lymphoma and follicular lymphoma.

15 point blockade is worthy of further study in follicular lymphoma.

16 ous rituximab is a mainstay of treatment for follicular lymphoma.

17 mptomatic, advanced-stage, low-tumour-burden follicular lymphoma.

18 dy, with rituximab in patients with relapsed follicular lymphoma.

19 propagates clonal evolution toward malignant follicular lymphoma.

20 ed tyrosine peptides in Burkitt lymphoma and follicular lymphoma.

21 overdue watershed moment in the treatment of follicular lymphoma.

22 slocation, which is strongly associated with follicular lymphoma.

23 udies have identified key genetic lesions in follicular lymphoma.

24 eatment of patients with relapsed/refractory follicular lymphoma.

25 major breakpoint region (MBR) to cause human follicular lymphoma.

26 grade 3b follicular lymphoma, or transformed follicular lymphoma.

27 e development, progression, and treatment of follicular lymphoma.

28 ng opportunities to improve the treatment of follicular lymphoma.

29 treated patients with relapsed or refractory follicular lymphoma.

30 refractory diffuse large B-cell lymphoma and follicular lymphoma.

31 tion in high-grade serous ovarian cancer and follicular lymphoma.

32 es of CBP/p300 loss-of-function mutations in follicular lymphoma.

33 0 loss-of-function mutations was observed in follicular lymphoma.

34 refractory diffuse large B-cell lymphoma and follicular lymphoma.

35 in the alteration of the immune landscape in follicular lymphoma.

36 tor effective in relapsed/refractory CLL and follicular lymphoma.

37 a new therapeutic option for advanced-stage follicular lymphoma.

38 refractory diffuse large B-cell lymphoma and follicular lymphoma.

39 patients with previously untreated advanced follicular lymphoma.

40 with rituximab-CVP (R-CVP) in patients with follicular lymphoma.

41 a (0 of 5), marginal zone lymphoma (0 of 6), follicular lymphoma (0 of 12), and diffuse large B-cell

42 ), diffuse large B-cell lymphoma (0.89), and follicular lymphoma (0.65).

43 were diffuse large B-cell lymphomas (32.4%), follicular lymphomas (15.3%), classic Hodgkin lymphomas

44 cytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffus

45 in RRAGC uniquely enriched in patients with follicular lymphoma (17%).

46 Of the 69 patients with primary follicular lymphoma, 38 (55%) presented with Ann Arbor s

47 ty patients were enrolled, including 34 with follicular lymphoma; 38 of 40 patients had previously re

48 esponse rate was 30%, including responses in follicular lymphoma (4 of 9) and DLBCL (2 of 5).

49 mas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas

50 Of 46 evaluable patients with follicular lymphoma, 40 (87%) patients had a complete re

51 Fifty-six patients were enrolled, most with follicular lymphoma (43%) or diffuse large B-cell lympho

52 For follicular lymphoma, 5-year net survival in northern Eur

53 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92).

54 of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 patients), small lymphocytic lym

55 ve response rates to monotherapy were 71% in follicular lymphoma, 78% in marginal zone lymphoma, 67%

56 mantle cell lymphoma (A051201) and relapsed follicular lymphoma (A051202).

57 mediastinal B-cell lymphoma, and transformed follicular lymphoma-according to the 2008 WHO Classifica

58 overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patien

59 We identified 13,988 follicular lymphoma and 25,320 diffuse large B-cell lymp

60 targeting EZH2 Y641 occur most frequently in follicular lymphoma and aggressive diffuse large B-cell

61 one of the most frequently mutated genes in follicular lymphoma and diffuse large B cell lymphoma; h

62 We considered follicular lymphoma and diffuse large B-cell lymphoma ca

63 Although survival for follicular lymphoma and diffuse large B-cell lymphoma is

64 ly, CBT has been relatively disappointing in follicular lymphoma and diffuse large B-cell lymphoma.

65 t lymphoma, nine BCL2 translocation-positive follicular lymphoma and four normal germinal center B ce

66 ogress in research and new therapies against follicular lymphoma and highlight the exciting opportuni

67 , undertaken at one instution, patients with follicular lymphoma and marginal zone lymphoma were give

68 f immune surveillance are lacking, including follicular lymphoma and most diffuse large B-cell lympho

69 Follicular lymphoma and multiple myeloma are clinically,

70 genetic evolution giving rise to relapse in follicular lymphoma and multiple myeloma, and discusses

71 a multicenter cohort study of patients with follicular lymphoma and subsequent biopsy-proven aggress

72 vides new insights into the genetic basis of follicular lymphoma and the clonal dynamics of transform

73 ents with histologically documented relapsed follicular lymphoma and time to progression 6 months or

74 aneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety d

75 ble patients had symptomatic, advanced stage follicular lymphoma and were previously untreated.

76 ing, which uncovered an ovarian carcinoma, a follicular lymphoma, and a Hodgkin lymphoma, each confir

77 hter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, w

78 tic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

79 itt's lymphoma, two of five with transformed follicular lymphoma, and four of eight with noncutaneous

80 compared with diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma.

81 Risks of chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma were 5%-10

82 om three B-NHL categories: Burkitt lymphoma, follicular lymphoma, and mantle-cell lymphoma.

83 s involving MYC in Burkitt lymphoma, BCL2 in follicular lymphoma, and MYC/BCL2/BCL6 in high-grade B-c

84 ed; 19 had diffuse large B-cell lymphoma, 53 follicular lymphoma, and one marginal zone lymphoma.

85 fuse large B-cell lymphoma, two patients had follicular lymphoma, and one patient had mantle cell lym

86 assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma.

87 eviously untreated grade 1-3a, CD20-positive follicular lymphoma at 67 centres in 23 countries.

88 Follicular lymphoma B cells undergo continuous somatic h

89 hts our current understanding of transformed follicular lymphoma biology and pathogenesis, current tr

90 alyse the mutation status of 74 genes in 151 follicular lymphoma biopsy specimens that were obtained

91 Although Burkitt lymphomas and follicular lymphomas both have features of germinal cent

92 om using TarPan Viewer on publicly available follicular lymphoma, breast cancer, and multiple myeloma

93 CL), mantle-cell lymphoma (MCL), transformed follicular lymphoma, Burkitt's lymphoma, or noncutaneous

94 r immune responses can improve the course of follicular lymphoma, but might be diminished by immune c

95 ls of most measured signaling nodes, whereas follicular lymphoma cells represented the opposite patte

96 Of the 21 patients in the follicular lymphoma cohort who received R-pina, 13 (62%,

97 In the follicular lymphoma cohort, grade 3-5 adverse events occ

98 as designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with

99 ased cohort of 107 patients with symptomatic follicular lymphoma considered ineligible for curative i

100 all lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and

101 e 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, myco

102 and three occurred in those with transformed follicular lymphoma DLBCL (n=5).

103 y untreated, CD20-positive grade 1, 2, or 3a follicular lymphoma; Eastern Co-operative Oncology Group

104 arge B-cell lymphoma (DLBCL) (15%, n = 118), follicular lymphoma (FL) (11%, n = 91), and mantle cell

105 oma (EMZL) (68.4% [180 of 263]), followed by follicular lymphoma (FL) (16.3% [43 of 263]), mantle cel

106 arginal-zone lymphoma (EMZL) (37% [n = 32]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B

107 ; 87.1%), patients with concurrent DLBCL and follicular lymphoma (FL) (n = 109; 8.2%) had fewer eleva

108 zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-

109 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longi

110 a or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemi

111 d outcomes associated with transformation of follicular lymphoma (FL) among 2652 evaluable patients p

112 scuss recently published studies centered on follicular lymphoma (FL) and diffuse large B-cell lympho

113 BBP is targeted by inactivating mutations in follicular lymphoma (FL) and diffuse large B-cell lympho

114 may play a role in the pathogenesis of human follicular lymphoma (FL) and other B cell malignancies.

115 In follicular lymphoma (FL) B cells, BCR expression is reta

116 es linked to surface immunoglobulin (sIg) of follicular lymphoma (FL) cells directly interact with en

117 We grew follicular lymphoma (FL) cells in vitro as multicellular

118 follicular lymphoma (PTNFL) is a variant of follicular lymphoma (FL) characterized by limited-stage

119 Follicular lymphoma (FL) constitutes the second most com

120 Most patients with follicular lymphoma (FL) experience multiple relapses ne

121 Twenty percent of patients with follicular lymphoma (FL) experience progression of disea

122 cl-2/IgH rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by p

123 These results extend the seminal study in follicular lymphoma (FL) from the National LymphoCare St

124 of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) has been dramatically enhanced

125 lthough the life expectancy of patients with follicular lymphoma (FL) has increased, little is known

126 Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified huma

127 r-type H+-translocating ATPase (v-ATPase) in follicular lymphoma (FL) highlights a role for the amino

128 Follicular lymphoma (FL) is a B-cell neoplasm resulting

129 Follicular lymphoma (FL) is a clinically and molecularly

130 Follicular lymphoma (FL) is a clinically and molecularly

131 Follicular lymphoma (FL) is a clinically and molecularly

132 Follicular lymphoma (FL) is a low-grade B-cell malignanc

133 Follicular lymphoma (FL) is a systemic neoplasm of the l

134 Follicular lymphoma (FL) is an indolent B-cell non-Hodgk

135 Purpose Follicular lymphoma (FL) is an indolent cancer, with eff

136 Follicular lymphoma (FL) is an indolent disease but tran

137 Follicular lymphoma (FL) is an indolent malignancy of ge

138 Follicular lymphoma (FL) is an indolent, yet incurable B

139 Follicular lymphoma (FL) is an uncurable cancer characte

140 Intraclonal heterogeneity in follicular lymphoma (FL) is apparent from studies of som

141 Follicular lymphoma (FL) is currently incurable using co

142 Advanced stage follicular lymphoma (FL) is incurable by conventional th

143 Follicular lymphoma (FL) is incurable with conventional

144 Follicular lymphoma (FL) is the most common form of indo

145 Follicular lymphoma (FL) is the most common form of indo

146 Follicular lymphoma (FL) is the most common indolent non

147 Follicular lymphoma (FL) is the most frequent indolent l

148 Follicular lymphoma (FL) is the most frequently occurrin

149 Follicular lymphoma (FL) is the second most common non-H

150 owever, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individual lesio

151 rly death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current

152 ated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome.

153 The prognosis of follicular lymphoma (FL) patients is suspected to be inf

154 s a critical event in the clinical course of follicular lymphoma (FL) patients.

155 mia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies

156 Follicular lymphoma (FL) represents more than 20% of all

157 is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optima

158 Follicular lymphoma (FL) results from the accumulation o

159 Transformation of follicular lymphoma (FL) to a more aggressive disease is

160 TAT3 in tumor-infiltrating T cells (TILs) in follicular lymphoma (FL) tumors, contrasting other non-H

161 A minority of patients with follicular lymphoma (FL) undergo histological transforma

162 have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIP

163 of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were calculated comparatively t

164 nobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of d

165 e follicular lymphoma (PTFL) is a variant of follicular lymphoma (FL) with distinctive clinicopatholo

166 Patients with follicular lymphoma (FL) with early relapse after initia

167 atients enrolled, including 12 patients with follicular lymphoma (FL), 16 with diffuse large B-cell l

168 The microenvironment of human follicular lymphoma (FL), an incurable B cell non-Hodgki

169 Here, we investigated this scenario in follicular lymphoma (FL), an indolent GC-derived maligna

170 Follicular lymphoma (FL), an indolent neoplasm caused by

171 We determined the ICT-GEP of Follicular Lymphoma (FL), and compared it with that of t

172 risk of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymph

173 The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquir

174 ormed follicular lymphoma (TF) as opposed to follicular lymphoma (FL), diagnosing transformation earl

175 In follicular lymphoma (FL), follicular helper T cells (TFH

176 Cs are also the origin of malignancy, namely follicular lymphoma (FL), GC B cell-diffuse large B cell

177 (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk

178 In low-tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has

179 Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell

180 Follicular lymphoma (FL), the second most common type of

181 e the complete pathogenic circuitry of human follicular lymphoma (FL), which activates or decommissio

182 ial therapy for patients with advanced-stage follicular lymphoma (FL).

183 c lymphocytic leukemia (CLL; B-cell CLL) and follicular lymphoma (FL).

184 ently identified many new genetic lesions in follicular lymphoma (FL).

185 in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).

186 y reflect tumor biology and host response in follicular lymphoma (FL).

187 mide and rituximab (LR) are active agents in follicular lymphoma (FL).

188 ab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).

189 itical early event in the natural history of follicular lymphoma (FL).

190 importance of the immune microenvironment in follicular lymphoma (FL).

191 t-line stand-alone therapy for patients with follicular lymphoma (FL).

192 ntation (HDC-ASCT) in patients with relapsed follicular lymphoma (FL).

193 nt in overall survival (OS) of patients with follicular lymphoma (FL).

194 to further characterize SNPs associated with follicular lymphoma (FL).

195 in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).

196 hronic lymphocytic B-cell leukemia (71%), in follicular lymphoma (FL, 70%), and in diffuse large B-ce

197 included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell l

198 Advanced follicular lymphomas (FL) are considered incurable with

199 Follicular lymphomas (FLs) are slow-growing, indolent tu

200 The genetic background of follicular lymphomas (FLs) diagnosed in advanced clinica

201 ma, primary mediastinal B-cell lymphoma, and follicular lymphoma grade 3B.

202 s (>=18 years) with histologically confirmed follicular lymphoma (grade 1, 2, 3a, or 3b) that had rel

203 th previously treated relapsed or refractory follicular lymphoma (grade 1, 2, or 3a) were included.

204 In phase 2, patients (age >/=18 years) with follicular lymphoma grades 1-3a were included.

205 ts (aged >/=18 years) with low-tumour-burden follicular lymphoma (grades 1, 2, and 3a) were randomly

206 ive, Ann Arbor stage II-IV DLBCL or grade 3b follicular lymphoma; had an Eastern Cooperative Oncology

207 Follicular lymphoma has been shown to be highly radiosen

208 Follicular lymphoma has been somewhat neglected by the r

209 ients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchf

210 e progression-free survival in patients with follicular lymphoma; however, the optimal duration of ma

211 ons differentially methylated in Burkitt and follicular lymphomas implicated DNA methylation as coope

212 gh rate early for both lymphomas, except for follicular lymphoma in northern Europe.

213 2002-04 periods for both cancers (except for follicular lymphoma in Scotland and Wales and diffuse la

214 re now available that target key pathways in follicular lymphoma including B-cell receptor signaling

215 both in combination, stratified by baseline follicular lymphoma International Prognostic Index (0-3

216 ients had stage III to IV disease, 37% had a Follicular Lymphoma International Prognostic Index (FLIP

217 EF2B, EP300, FOXO1, CREBBP, and CARD11), the Follicular Lymphoma International Prognostic Index (FLIP

218 for poor outcomes to first-line therapy (m7-Follicular Lymphoma International Prognostic Index [m7-F

219 Randomisation was stratified by Follicular Lymphoma International Prognostic Index risk

220 "B" symptoms, histologic grade 3a, and high Follicular Lymphoma International Prognostic Index score

221 cyclophosphamide, vincristine, prednisone), Follicular Lymphoma International Prognostic Index score

222 apy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score

223 0 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score

224 c Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score

225 s and was stratified by country, gender, and Follicular Lymphoma International Prognostic Index score

226 ion was stratified by selected chemotherapy, Follicular Lymphoma International Prognostic Index, and

227 erapy-treated patients was additional to the Follicular Lymphoma International Prognostic Index.

228 e intermediate or high risk according to the Follicular Lymphoma International Prognostic Index.

229 Follicular lymphoma is a clinically and genetically hete

230 Follicular lymphoma is a very common and still incurable

231 Follicular lymphoma is an incurable B cell malignancy ch

232 Follicular lymphoma is an incurable malignancy, with tra

233 Chemoimmunotherapy in follicular lymphoma is associated with significant toxic

234 with chemotherapy in patients with untreated follicular lymphoma is in progress.

235 kin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-

236 prostate, colon, rectum, lung, and liver and follicular lymphoma, melanoma, and AML.

237 Minor changes (2.3%) mostly consisted of follicular lymphoma misgrading and diffuse large B-cell

238 Among patients with follicular lymphoma (n = 149), ORR seemed higher for obi

239 Patients presenting with stage IIIE-IV follicular lymphoma (n = 20) most frequently received ch

240 ipheral T-cell lymphoma (n = 8), transformed follicular lymphoma (n = 5), and Burkitt's (n = 1).

241 Patients with primary follicular lymphoma (n = 69) and those with isolated ocu

242 110 patients with follicular lymphoma (n=50), marginal zone lymphoma (n=30

243 Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lympho

244 , advanced stage (Ann Arbor stage III or IV) follicular lymphoma of WHO histological grades 1, 2, or

245 ynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in

246 changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma.

247 or radical or palliative local control, with follicular lymphoma or marginal zone lymphoma, who had r

248 all lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma.

249 with relapsed or refractory DLBCL, grade 3b follicular lymphoma, or transformed follicular lymphoma.

250 mab and lenalidomide in previously untreated follicular lymphoma (overall response rate [ORR] 90%-96%

251 nal zone lymphoma (P-interaction = 0.02) and follicular lymphoma (P-interaction = 0.04).

252 e B-cell lymphoma vs one of 15 patients with follicular lymphoma; P = .047) and with advanced stage d

253 encing on 10 follicular lymphoma-transformed follicular lymphoma pairs followed by deep sequencing of

254 slocations present in lymph node biopsies of follicular lymphoma patents.

255 vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy

256 However, in 20% to 60% of follicular lymphoma patients, transformation to aggressi

257 ells from high-grade compared with low-grade follicular lymphoma patients.

258 Patients with ocular adnexal follicular lymphoma primarily treated with EBRT had a mo

259 Pediatric-type follicular lymphoma (PTFL) is a B-cell lymphoma with dis

260 Pediatric-type follicular lymphoma (PTFL) is a variant of follicular ly

261 Pediatric-type nodal follicular lymphoma (PTNFL) is a variant of follicular l

262 Previously untreated patients with follicular lymphoma received rituximab 375 mg/m(2) on da

263 s improves prognostication for patients with follicular lymphoma receiving first-line immunochemother

264 =18 years) patients with rituximab-sensitive follicular lymphoma relapsing after one to four previous

265 ted to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective

266 0 weeks, 60% and 36% of patients with CLL or follicular lymphoma, respectively, achieved objective re

267 7, 95% confidence interval: 1.12, 5.04) with follicular lymphoma risk.

268 Comparison of Burkitt and follicular lymphoma samples showed differential methylat

269 one lymphoma subtypes as well as age for the follicular lymphoma subtype.

270 arly stage diffuse large B-cell lymphoma and follicular lymphoma suggests better delineation of disea

271 different treatment strategy for transformed follicular lymphoma (TF) as opposed to follicular lympho

272 tients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory

273 tients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relaps

274 Follicular lymphoma, the most common indolent subtype of

275 Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphom

276 rkitt lymphoma was more likely than indolent follicular lymphoma to express matriptase alone (86% ver

277 a ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with R

278 In follicular lymphoma, traditionally viewed as an incurabl

279 od for identifying bona fide contributors to follicular lymphoma transformation and may therefore gui

280 cific functional and genetic determinants of follicular lymphoma transformation remain elusive, and g

281 B-cell-specific regulatory model exhibiting follicular lymphoma transformation signatures using the

282 Therefore, to identify candidate drivers of follicular lymphoma transformation, we performed systema

283 whole-genome or whole-exome sequencing on 10 follicular lymphoma-transformed follicular lymphoma pair

284 lenalidomide with rituximab in patients with follicular lymphoma treated in the CALGB 50401 (Alliance

285 ) with minimisation stratified by histology (follicular lymphoma vs marginal zone lymphoma), treatmen

286 01) plus chemotherapy in relapsed/refractory follicular lymphoma was explored in 56 patients.

287 8 years or older with Ann Arbor stage III-IV follicular lymphoma were assigned 1:1 to CVP plus intrav

288 e large B-cell lymphoma and 41 patients with follicular lymphoma were eligible for analysis.

289 ge B-cell lymphoma, mantle-cell lymphoma, or follicular lymphoma were enrolled.

290 with previously untreated high-tumor-burden follicular lymphoma were nonrandomly assigned to receive

291 th diffuse large B-cell lymphoma and 42 with follicular lymphoma were recruited between Sept 27, 2012

292 relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of ritu

293 BCL2, 11 of 25 DHITsig-positive-transformed follicular lymphomas were classified as HGBL-DH/TH- BCL2

294 ree with mantle cell lymphoma and eight with follicular lymphoma) were enrolled.

295 A051201 (mantle cell lymphoma) and A051202 (follicular lymphoma) were phase 1 trials.

296 (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98

297 mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite u

298 nderwent autologous HSCT, 6 for MG and 1 for follicular lymphoma with coincident active MG.

299 PET can predict prognosis for patients with follicular lymphoma with high tumour burden at the end o

300 pleted patient treated with obinutuzumab for follicular lymphoma with protracted COVID-19 and viremia